Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
64 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2014', provides an overview of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview 8 Therapeutics Development 9 Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Overview 9 Pipeline Products for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis 10 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Development by Companies 11 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes 13 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Development by Companies 16 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Products under Investigation by Universities/Institutes 17 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Companies Involved in Therapeutics Development 18 AlphaVax, Inc. 18 CEL-SCI Corporation 19 GeneCure LLC 20 Humabs BioMed SA 21 Kineta, Inc. 22 Myelo Therapeutics GmbH 23 Novavax, Inc. 24 Planet Biotechnology Inc. 25 Protein Sciences Corporation 26 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 CEL-1000 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 D-3252 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 EMER-IT - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 IKT-014 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ML-188 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 MMCatLMC - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Monoclonal Antibodies for SARS Virus Infections - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Monoclonal Antibody for MERS and SARS - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Myelo-001 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 oxocarbazate - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 rOAS - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 SARS Vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 SARS vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SARS vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SARS Vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 SARS-CoV Vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 severe acute respiratory syndrome vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule for SARS - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Synthetic Peptide to Target Spike Protein for SARS Infection - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 thiocarbazate - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Vaccine for Respiratory and Infectious Diseases - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Recent Pipeline Updates 58 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects 59 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products 61 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Product Development Milestones 62 Featured News & Press Releases 62 May 19, 2014: Kineta's Novel Antiviral Drugs Show Encouraging Efficacy Against Dengue And SARS Viruses 62 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 64 Disclaimer 64
List of Tables Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, H2 2014 9 Number of Products under Development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by AlphaVax, Inc., H2 2014 18 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by CEL-SCI Corporation, H2 2014 19 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by GeneCure LLC, H2 2014 20 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Humabs BioMed SA, H2 2014 21 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Kineta, Inc., H2 2014 22 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Myelo Therapeutics GmbH, H2 2014 23 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Novavax, Inc., H2 2014 24 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Planet Biotechnology Inc., H2 2014 25 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline by Protein Sciences Corporation, H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 30 Number of Products by Stage and Route of Administration, H2 2014 32 Number of Products by Stage and Molecule Type, H2 2014 34 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Therapeutics - Recent Pipeline Updates, H2 2014 58 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects, H2 2014 59 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Dormant Projects (Contd..1), H2 2014 60 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Discontinued Products, H2 2014 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.